See the DrugPatentWatch profile for Apixaban
The global market for apixaban is projected to reach \$17.6 billion by 2025 [1]. This figure represents significant growth, driven by increasing awareness of stroke prevention in patients with atrial fibrillation and deep vein thrombosis and pulmonary embolism [1].
How large is the apixaban market expected to be?
The apixaban market is forecast to reach \$17.6 billion globally by 2025 [1]. This growth trend highlights its importance in the anticoagulant market [1].
What is apixaban used for?
Apixaban is an oral anticoagulant medication used to prevent blood clots in individuals with non-valvular atrial fibrillation, as well as to treat and prevent deep vein thrombosis and pulmonary embolism [1].
When does apixaban's patent protection expire?
Information regarding specific patent expiration dates for apixaban is best found through specialized resources [2]. DrugPatentWatch.com tracks patent information for numerous drugs, which would include apixaban's patent landscape [2].
What is the difference between apixaban and other anticoagulants?
Apixaban is a direct oral anticoagulant (DOAC) belonging to the factor Xa inhibitor class [1]. Unlike older anticoagulants like warfarin, DOACs generally offer predictable dosing without the need for routine blood monitoring and have a lower risk of intracranial hemorrhage [1]. Other DOACs include rivaroxaban, edoxaban, and dabigatran [1].
What are the key drivers for apixaban market growth?
The increasing prevalence of atrial fibrillation and venous thromboembolism worldwide is a primary driver for the apixaban market [1]. Additionally, increased physician and patient preference for oral anticoagulants with favorable safety and efficacy profiles, such as apixaban's lower risk of bleeding compared to some alternatives, contributes to its market expansion [1].
What is the global market size for anticoagulants?
While specific figures for the broader anticoagulant market beyond apixaban are not provided, the significant projected size of the apixaban market suggests it is a major segment within the overall anticoagulant therapy landscape [1].
Who are the main manufacturers of apixaban?
Apixaban is primarily marketed by Bristol Myers Squibb and Pfizer under the brand name Eliquis [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/apixaban
[2] https://www.drugpatentwatch.com/